Bicara Therapeutics Business Summary

Bicara Therapeutics Inc. (BCAX) is a clinical-stage biopharmaceutical company that operates on a research-and-development-driven business model, primarily generating capital through equity financing and public offerings, such as its $150 million raise in February 2026. The company focuses on the development of first-in-class bifunctional antibodies designed to modulate the tumor microenvironment. Its primary business segment is centered on its lead candidate, ficerafusp alfa (BCA101), which is currently in Phase 3 clinical trials for head and neck squamous cell carcinoma (HNSCC). Bicara competes directly with other oncology-focused biotechnology firms such as Merus N.V., Xencor, Inc., and Cullinan Therapeutics, positioning itself as a specialist in dual-action biologics that combine EGFR-directed antibodies with TGF-β traps to overcome immune exclusion in solid tumors. The company was founded in 2019 with significant backing from Biocon and is led by Chief Executive Officer Claire Mazumdar, PhD, MBA, who previously served as a venture partner at RA Capital Management. The executive leadership team includes President and COO Ryan Cohlhepp, PharmD, formerly of Tesaro and Takeda, Chief Financial Officer Ivan Hyep, and Chief Medical Officer David Raben, MD. The board is chaired by Michael Powell, PhD, a General Partner at Sofinnova Investments, and includes notable industry figure Kiran Mazumdar-Shaw, Executive Chairperson of Biocon. Bicara is supported by a high-pedigree investor base including TPG Capital, RA Capital Management, Red Tree Venture Capital, and T. Rowe Price, reflecting strong institutional confidence in its bifunctional platform.